L01XX19 • irinotecan • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Irinotecan is a chemotherapy medication used to treat metastatic colorectal cancer, usually in combination with other drugs. It works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication in cancer cells, thereby causing their death.
The medication is administered intravenously under the supervision of an oncologist, and the dosage is adjusted based on body weight and the patient's overall condition.
Side effects may include severe diarrhea, nausea, vomiting, decreased blood cell counts, or hair loss. In rare cases, severe allergic reactions or liver toxicity may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should not use this medication.
Substance: irinotecan
Date of last drug list: 01-07-2015
Commercial code: W52802004
Concentration: 20mg / ml
Pharmaceutical form: perfusive solution concentrate
Quantity: 1
Product type: original
Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.